Across 236 whole-genome sequencing osteosarcoma samples, five genomic hotspots of clustered structural variation collectively altered in 58% of tumors were uncovered, and localized transcriptional dysregulation at hotspot event loci was found, linking these structural alterations to a less differentiated cell state.
Abstract
The genomic landscape of osteosarcoma, the most common bone cancer worldwide, is among the most structurally complex of all human malignancies. The identification of recurrent and functionally consequential patterns has thus remained a challenge. Across 236 whole-genome sequencing osteosarcoma samples, we uncovered five genomic hotspots of clustered structural variation collectively altered in 58% of tumors. Four were associated with amplification of oncogenes (MYC, CCND3, CCNE1, CDK4), while the fifth mapped largely upstream of TP53. Hotspot events showed coordinated patterns of co-occurrence and mutual exclusivity with each other and with tumor suppressor alterations, suggesting genomic context-specific selection. We found localized transcriptional dysregulation at hotspot event loci, and single cells harboring these events converged on a neural crest-like program, linking these structural alterations to a less differentiated cell state. These events were also detectable non-invasively through liquid biopsies and displayed ongoing structural evolution throughout disease progression, a finding with potential clinical utility. Our results provide novel insight into how complex rearrangements shape oncogenesis in osteosarcoma, with broader relevance to other cancers characterized by complex genomes.
High-coverage whole-genome sequencing, large-scale transcriptomics, and eQTL are used to map male cancer cell lines, revealing a region-specific LOY landscape with recurrent euchromatic deletions affecting protein-coding genes and non-coding elements and motivating validation in primary tumor cohorts.
Trini Nguyen, Aditi Kuchi, Hong-Yu Liu et al.· Communications Biology· 0 citations
It is proposed that MEK inhibitors may represent a relevant therapeutic option for BRAF fusions and non‐V600 BRAF mutant tumours, providing a novel strategy for this challenging disease.
Matilde Monti, Martina Brigida Romanello, L. Agnelli et al.· Journal of Pathology· 0 citations
TP53 and FOXA1 mutations, observed in primary and metastatic castration-resistant prostate cancer, were associated with aggressive disease phenotypes and potential therapeutic resistance, and these findings highlight TP53 and FOXA1 as promising biomarkers and potential therapeutic targets in prostate cancer.
A framework for understanding how early-established genomic backbones and regional transcriptional plasticity jointly drive phenotypic diversity is provided for understanding how genomic diversification intersects with transcriptional plasticity remains incompletely understood.
Serafiina Ohlsbom, S. Mäntylä, R. Nätkin et al.· bioRxiv· 0 citations
The data suggest that despite the heterogeneity in CRC, genomic evolution increases the impact of recurrent alterations, and integrating information about tumor primary location and genomics can be used to predict organ-specific metastasis risk.
Paolo Manca, H. Walch, Jierui Xu et al.· Cancer Cell· 1 citation
Chromosomal translocations are central drivers of hematologic malignancies, reshaping gene regulation, altering epigenetic states, and generating oncogenic fusion proteins that initiate and sustain malignant transformation. Advances in whole-genome sequencing, long-read mapping, and single-cell multiomics have expanded...
E. I. Obeagu, Abraham John Chuwkwuebuka, E. Abdalhabib· Universal Journal of Pharmac...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.